கீமோ அனுபவம் இன்றி வார்ப்பு எதிர்ப்பு ப்ராஸ்டேட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results
News provided by
Share this article
Share this article
RARITAN, N.J., Feb. 2, 2021 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA
® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. ....

United States , Craig Tendler , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , Global Medical Affairs , Breadth Of Ongoing Clinical Development Program , Janssen Biotech Inc , Tesaro Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Prognostic Association Between Common Laboratory , Clinical Development , None Of The Janssen Pharmaceutical Companies , Astex Pharmaceuticals , Janssen Research Development Llcor , Exchange Commission , Companies Of Johnson , Single Payer Health , American Society , Clinical Oncology Genitourinary , Cancers Symposium , Vice President , Janssen Research ,